References

1. Alzheimer’s Association. 2016 Alzheimer’s Disease Facts and Figures. Alzheimers Dement. J. Alzheimers Assoc. 2016, 12, 459–509.
2. Braak, H.; Braak, E. Alzheimer’s Disease: Striatal Amyloid Deposits and Neurofibrillary Changes. J. Neuropathol. Exp. Neurol. 1990, 49, 215–224.
3. Selkoe, D.J.; Hardy, J. The Amyloid Hypothesis of Alzheimer’s Disease at 25 Years. EMBO Mol. Med. 2016, 8, 595–608.
4. Grimm, M.O.W.; Mett, J.; Grimm, H.S.; Hartmann, T. APP Function and Lipids: A Bidirectional Link. Front. Mol. Neurosci. 2017, 10, 63.
5. Chew, H.; Solomon, V.A.; Fonteh, A.N. Involvement of Lipids in Alzheimer’s Disease Pathology and Potential Therapies. Front. Physiol. 2020, 11, 598.
6. Maltsev, A.V.; Bystryak, S.; Galzitskaya, O.V. The Role of β-Amyloid Peptide in Neurodegenerative Diseases. Ageing Res. Rev. 2011, 10, 440–452.
7. Cummings, J.L.; Kaufer, D. Neuropsychiatric Aspects of Alzheimer’s Disease: The Cholinergic Hypothesis Revisited. Neurology 1996, 47, 876–883.
8. Chun, W.; Johnson, G.V.W. The Role of Tau Phosphorylation and Cleavage in Neuronal Cell Death. Front. Biosci. J. Virtual Libr. 2007, 12, 733–756.
9. Yang, G.; Zhou, R.; Zhou, Q.; Guo, X.; Yan, C.; Ke, M.; Lei, J.; Shi, Y. Structural Basis of Notch Recognition by Human γ-Secretase. Nature 2019, 565, 192–197.
10. Hardy, J.; Allsop, D. Amyloid Deposition as the Central Event in the Aetiology of Alzheimer’s Disease. Trends Pharmacol. Sci. 1991, 12, 383–388.
11. Mudher, A.; Lovestone, S. Alzheimer’s Disease—Do Tauists and Baptists Finally Shake Hands? Trends Neurosci. 2002, 25, 22–26.
12. Chávez-Gutiérrez, L.; Szaruga, M. Mechanisms of Neurodegeneration—Insights from Familial Alzheimer’s Disease. Semin. Cell Dev. Biol. 2020, 105, 75–85.
13. Szaruga, M.; Munteanu, B.; Lismont, S.; Veugelen, S.; Horré, K.; Mercken, M.; Saido, T.C.; Ryan, N.S.; De Vos, T.; Savvides, S.N.; et al. Alzheimer’s-Causing Mutations Shift Aβ Length by Destabilizing γ-Secretase-Aβn Interactions. Cell 2017, 170, 443–456.e14.
14. Lott, I.T.; Head, E. Alzheimer Disease and Down Syndrome: Factors in Pathogenesis. Neurobiol. Aging 2005, 26, 383–389.
15. Li, S.; Selkoe, D.J. A Mechanistic Hypothesis for the Impairment of Synaptic Plasticity by Soluble Aβ Oligomers from Alzheimer’s Brain. J. Neurochem. 2020, 154, 583–597.
16. Giuffrida, M.L.; Caraci, F.; Pignataro, B.; Cataldo, S.; De Bona, P.; Bruno, V.; Molinaro, G.; Pappalardo, G.; Messina, A.; Palmigiano, A.; et al. Beta-Amyloid Monomers Are Neuroprotective. J. Neurosci. Off. J. Soc. Neurosci. 2009, 29, 10582–10587.
17. Soscia, S.J.; Kirby, J.E.; Washicosky, K.J.; Tucker, S.M.; Ingelsson, M.; Hyman, B.; Burton, M.A.; Goldstein, L.E.; Duong, S.; Tanzi, R.E.; et al. The Alzheimer’s Disease-Associated Amyloid Beta-Protein Is an Antimicrobial Peptide. PLoS ONE 2010, 5, e9505.
18. Kumar, D.K.V.; Choi, S.H.; Washicosky, K.J.; Eimer, W.A.; Tucker, S.; Ghofrani, J.; Lefkowitz, A.; McColl, G.; Goldstein, L.E.; Tanzi, R.E.; et al. Amyloid-β Peptide Protects against Microbial Infection in Mouse and Worm Models of Alzheimer’s Disease. Sci. Transl. Med. 2016, 8, 340ra72.
19. Gosztyla, M.L.; Brothers, H.M.; Robinson, S.R. Alzheimer’s Amyloid-β Is an Antimicrobial Peptide: A Review of the Evidence. J. Alzheimers Dis. JAD 2018, 62, 1495–1506.
20. Deyts, C.; Thinakaran, G.; Parent, A.T. APP Receptor? To Be or Not To Be. Trends Pharmacol. Sci. 2016, 37, 390–411.
21. Rossjohn, J.; Cappai, R.; Feil, S.C.; Henry, A.; McKinstry, W.J.; Galatis, D.; Hesse, L.; Multhaup, G.; Beyreuther, K.; Masters, C.L.; et al. Crystal Structure of the N-Terminal, Growth Factor-like Domain of Alzheimer Amyloid Precursor Protein. Nat. Struct. Biol. 1999, 6, 327–331.
22. Barnham, K.J.; McKinstry, W.J.; Multhaup, G.; Galatis, D.; Morton, C.J.; Curtain, C.C.; Williamson, N.A.; White, A.R.; Hinds, M.G.; Norton, R.S.; et al. Structure of the Alzheimer’s Disease Amyloid Precursor Protein Copper Binding Domain: A REGULATOR OF NEURONAL COPPER HOMEOSTASIS. J. Biol. Chem. 2003, 278, 17401–17407.
23. Nadezhdin, K.D.; Bocharova, O.V.; Bocharov, E.V.; Arseniev, A.S. Dimeric Structure of Transmembrane Domain of Amyloid Precursor Protein in Micellar Environment. FEBS Lett. 2012, 586, 1687–1692.
24. Istrate, A.N.; Kozin, S.A.; Zhokhov, S.S.; Mantsyzov, A.B.; Kechko, O.I.; Pastore, A.; Makarov, A.A.; Polshakov, V.I. Interplay of Histidine Residues of the Alzheimer’s Disease Aβ Peptide Governs Its Zn-Induced Oligomerization. Sci. Rep. 2016, 6, 21734.
25. Lin, X.; Koelsch, G.; Wu, S.; Downs, D.; Dashti, A.; Tang, J. Human Aspartic Protease Memapsin 2 Cleaves the β-Secretase Site of β-Amyloid Precursor Protein. Proc. Natl. Acad. Sci. USA 2000, 97, 1456–1460.
26. Bittner, H.J.; Guixà-González, R.; Hildebrand, P.W. Structural Basis for the Interaction of the Beta-Secretase with Copper. Biochim. Biophys. Acta BBA Biomembr. 2018, 1860, 1105–1113.
27. Zhang, X.; Li, Y.; Xu, H.; Zhang, Y. The γ-Secretase Complex: From Structure to Function. Front. Cell. Neurosci. 2014, 8.
28. Gralle, M.; Oliveira, C.L.P.; Guerreiro, L.H.; McKinstry, W.J.; Galatis, D.; Masters, C.L.; Cappai, R.; Parker, M.W.; Ramos, C.H.I.; Torriani, I.; et al. Solution Conformation and Heparin-Induced Dimerization of the Full-Length Extracellular Domain of the Human Amyloid Precursor Protein. J. Mol. Biol. 2006, 357, 493–508.
29. Svergun, D.I.; Petoukhov, M.V.; Koch, M.H. Determination of Domain Structure of Proteins from X-Ray Solution Scattering. Biophys. J. 2001, 80, 2946–2953.
30. Konarev, P.V.; Petoukhov, M.V.; Svergun, D.I. MASSHA—A Graphics System for Rigid-Body Modelling of Macromolecular Complexes against Solution Scattering Data. J. Appl. Crystallogr. 2001, 34, 527–532.
31. Scheidig, A.J.; Hynes, T.R.; Pelletier, L.A.; Wells, J.A.; Kossiakoff, A.A. Crystal Structures of Bovine Chymotrypsin and Trypsin Complexed to the Inhibitor Domain of Alzheimer’s Amyloid β-Protein Precursor (APPI) and Basic Pancreatic Trypsin Inhibitor (BPTI): Engineering of Inhibitors with Altered Specificities. Protein Sci. 1997, 6, 1806–1824.
32. Tsvetkov, P.O.; Kulikova, A.A.; Golovin, A.V.; Tkachev, Y.V.; Archakov, A.I.; Kozin, S.A.; Makarov, A.A. Minimal Zn(2+) Binding Site of Amyloid-β. Biophys. J. 2010, 99, L84–L86.
33. Kozin, S.A.; Mezentsev, Y.V.; Kulikova, A.A.; Indeykina, M.I.; Golovin, A.V.; Ivanov, A.S.; Tsvetkov, P.O.; Makarov, A.A. Zinc-Induced Dimerization of the Amyloid-β Metal-Binding Domain 1-16 Is Mediated by Residues 11-14. Mol. Biosyst. 2011, 7, 1053–1055.
34. Nadezhdin, K.D.; Bocharova, O.V.; Bocharov, E.V.; Arseniev, A.S. Structural and Dynamic Study of the Transmembrane Domain of the Amyloid Precursor Protein. Acta Nat. 2011, 3, 69–76.
35. Mackenzie, K.R. Folding and Stability of Alpha-Helical Integral Membrane Proteins. Chem. Rev. 2006, 106, 1931–1977.
36. Barrett, P.J.; Song, Y.; Van Horn, W.D.; Hustedt, E.J.; Schafer, J.M.; Hadziselimovic, A.; Beel, A.J.; Sanders, C.R. The Amyloid Precursor Protein Has a Flexible Transmembrane Domain and Binds Cholesterol. Science 2012, 336, 1168–1171.
37. Beel, A.J.; Mobley, C.K.; Kim, H.J.; Tian, F.; Hadziselimovic, A.; Jap, B.; Prestegard, J.H.; Sanders, C.R. Structural Studies of the Transmembrane C-Terminal Domain of the Amyloid Precursor Protein (APP): Does APP Function as a Cholesterol Sensor? Biochemistry 2008, 47, 9428–9446.
38. Götz, A.; Mylonas, N.; Högel, P.; Silber, M.; Heinel, H.; Menig, S.; Vogel, A.; Feyrer, H.; Huster, D.; Luy, B.; et al. Modulating Hinge Flexibility in the APP Transmembrane Domain Alters γ-Secretase Cleavage. Biophys. J. 2019, 116, 2103–2120.
39. Bocharov, E.V.; Nadezhdin, K.D.; Urban, A.S.; Volynsky, P.E.; Pavlov, K.V.; Efremov, R.G.; Arseniev, A.S.; Bocharova, O.V. Familial L723P Mutation Can Shift the Distribution between the Alternative APP Transmembrane Domain Cleavage Cascades by Local Unfolding of the Ε-Cleavage Site Suggesting a Straightforward Mechanism of Alzheimer’s Disease Pathogenesis. ACS Chem. Biol. 2019, 14, 1573–1582.
40. Itkin, A.; Salnikov, E.S.; Aisenbrey, C.; Raya, J.; Glattard, E.; Raussens, V.; Ruysschaert, J.-M.; Bechinger, B. Structural Characterization of the Amyloid Precursor Protein Transmembrane Domain and Its γ-Cleavage Site. ACS Omega 2017, 2, 6525–6534.
41. Chen, W.; Gamache, E.; Rosenman, D.J.; Xie, J.; Lopez, M.M.; Li, Y.-M.; Wang, C. Familial Alzheimer’s Mutations within APPTM Increase Aβ42 Production by Enhancing Accessibility of ε-Cleavage Site. Nat. Commun. 2014, 5, 3037.
42. Sato, T.; Tang, T.-C.; Reubins, G.; Fei, J.Z.; Fujimoto, T.; Kienlen-Campard, P.; Constantinescu, S.N.; Octave, J.-N.; Aimoto, S.; Smith, S.O. A Helix-to-Coil Transition at the Epsilon-Cut Site in the Transmembrane Dimer of the Amyloid Precursor Protein Is Required for Proteolysis. Proc. Natl. Acad. Sci. USA 2009, 106, 1421–1426.
43. Dominguez, L.; Foster, L.; Straub, J.E.; Thirumalai, D. Impact of Membrane Lipid Composition on the Structure and Stability of the Transmembrane Domain of Amyloid Precursor Protein. Proc. Natl. Acad. Sci. USA 2016, 113, E5281–E5287.
44. Eggert, S.; Midthune, B.; Cottrell, B.; Koo, E.H. Induced Dimerization of the Amyloid Precursor Protein (APP) Leads to Decreased Amyloid-Beta Protein (Abeta) Production. J. Biol. Chem. 2009.
45. Hunter, S.; Brayne, C. Understanding the Roles of Mutations in the Amyloid Precursor Protein in Alzheimer Disease. Mol. Psychiatry 2018, 23, 81–93.
46. Langosch, D.; Scharnagl, C.; Steiner, H.; Lemberg, M.K. Understanding Intramembrane Proteolysis: From Protein Dynamics to Reaction Kinetics. Trends Biochem. Sci. 2015, 40, 318–327.
47. Tang, T.-C.; Hu, Y.; Kienlen-Campard, P.; El Haylani, L.; Decock, M.; Van Hees, J.; Fu, Z.; Octave, J.-N.; Constantinescu, S.N.; Smith, S.O. Conformational Changes Induced by the A21G Flemish Mutation in the Amyloid Precursor Protein Lead to Increased Aβ Production. Structure 2014, 22, 387–396.
48. Polshakov, V.I.; Mantsyzov, A.B.; Kozin, S.A.; Adzhubei, A.A.; Zhokhov, S.S.; van Beek, W.; Kulikova, A.A.; Indeykina, M.I.; Mitkevich, V.A.; Makarov, A.A. A Binuclear Zinc Interaction Fold Discovered in the Homodimer of Alzheimer’s Amyloid-β Fragment with Taiwanese Mutation D7H. Angew. Chem. Int. Ed. Engl. 2017, 56, 11734–11739.
49. Götz, A.; Högel, P.; Silber, M.; Chaitoglou, I.; Luy, B.; Muhle-Goll, C.; Scharnagl, C.; Langosch, D. Increased H-Bond Stability Relates to Altered ε-Cleavage Efficiency and Aβ Levels in the I45T Familial Alzheimer’s Disease Mutant of APP. Sci. Rep. 2019, 9, 5321.
50. Ramelot, T.A.; Gentile, L.N.; Nicholson, L.K. Transient Structure of the Amyloid Precursor Protein Cytoplasmic Tail Indicates Preordering of Structure for Binding to Cytosolic Factors. Biochemistry 2000, 39, 2714–2725.
51. Radzimanowski, J.; Simon, B.; Sattler, M.; Beyreuther, K.; Sinning, I.; Wild, K. Structure of the Intracellular Domain of the Amyloid Precursor Protein in Complex with Fe65-PTB2. EMBO Rep. 2008, 9, 1134–1140.
52. Li, H.; Koshiba, S.; Hayashi, F.; Tochio, N.; Tomizawa, T.; Kasai, T.; Yabuki, T.; Motoda, Y.; Harada, T.; Watanabe, S.; et al. Structure of the C-Terminal Phosphotyrosine Interaction Domain of Fe65L1 Complexed with the Cytoplasmic Tail of Amyloid Precursor Protein Reveals a Novel Peptide Binding Mode. J. Biol. Chem. 2008, 283, 27165–27178.
53. Shu, R.; Wong, W.; Ma, Q.H.; Yang, Z.Z.; Zhu, H.; Liu, F.J.; Wang, P.; Ma, J.; Yan, S.; Polo, J.M.; et al. APP Intracellular Domain Acts as a Transcriptional Regulator of MiR-663 Suppressing Neuronal Differentiation. Cell Death Dis. 2015, 6, e1651.
54. Copenhaver, P.F.; Kögel, D. Role of APP Interactions with Heterotrimeric G Proteins: Physiological Functions and Pathological Consequences. Front. Mol. Neurosci. 2017, 10, 3.
55. Copani, A. The Underexplored Question of β-Amyloid Monomers. Eur. J. Pharmacol. 2017, 817, 71–75.
56. Parihar, M.S.; Brewer, G.J. Amyloid-β as a Modulator of Synaptic Plasticity. J. Alzheimers Dis. JAD 2010, 22, 741–763.
57. Wang, H.; Megill, A.; He, K.; Kirkwood, A.; Lee, H.-K. Consequences of Inhibiting Amyloid Precursor Protein Processing Enzymes on Synaptic Function and Plasticity. Neural Plast. 2012, 2012, 272374.
58. Giuffrida, M.L.; Caraci, F.; De Bona, P.; Pappalardo, G.; Nicoletti, F.; Rizzarelli, E.; Copani, A. The Monomer State of Beta-Amyloid: Where the Alzheimer’s Disease Protein Meets Physiology. Rev. Neurosci. 2010, 21.
59. Plant, L.D.; Boyle, J.P.; Smith, I.F.; Peers, C.; Pearson, H.A. The Production of Amyloid β Peptide Is a Critical Requirement for the Viability of Central Neurons. J. Neurosci. 2003, 23, 5531–5535.
60. Barry, A.E.; Klyubin, I.; Mc Donald, J.M.; Mably, A.J.; Farrell, M.A.; Scott, M.; Walsh, D.M.; Rowan, M.J. Alzheimer’s Disease Brain-Derived Amyloid-β-Mediated Inhibition of LTP in Vivo Is Prevented by Immunotargeting Cellular Prion Protein. J. Neurosci. Off. J. Soc. Neurosci. 2011, 31, 7259–7263.
61. Han, S.-H.; Kim, Y.H.; Mook-Jung, I. RAGE: The Beneficial and Deleterious Effects by Diverse Mechanisms of Actions. Mol. Cells 2011, 31, 91–97.
62. Rhein, V.; Song, X.; Wiesner, A.; Ittner, L.M.; Baysang, G.; Meier, F.; Ozmen, L.; Bluethmann, H.; Dröse, S.; Brandt, U.; et al. Amyloid-Beta and Tau Synergistically Impair the Oxidative Phosphorylation System in Triple Transgenic Alzheimer’s Disease Mice. Proc. Natl. Acad. Sci. USA 2009, 106, 20057–20062.
63. Hane, F.; Leonenko, Z. Effect of Metals on Kinetic Pathways of Amyloid-β Aggregation. Biomolecules 2014, 4, 101–116.
64. Caughey, B.; Lansbury, P.T. PROTOFIBRILS, PORES, FIBRILS, AND NEURODEGENERATION: Separating the Responsible Protein Aggregates from The Innocent Bystanders. Annu. Rev. Neurosci. 2003, 26, 267–298.
65. Crescenzi, O.; Tomaselli, S.; Guerrini, R.; Salvadori, S.; D’Ursi, A.M.; Temussi, P.A.; Picone, D. Solution Structure of the Alzheimer Amyloid Beta-Peptide (1-42) in an Apolar Microenvironment. Similarity with a Virus Fusion Domain. Eur. J. Biochem. 2002, 269, 5642–5648.
66. Tomaselli, S.; Esposito, V.; Vangone, P.; van Nuland, N.A.J.; Bonvin, A.M.J.J.; Guerrini, R.; Tancredi, T.; Temussi, P.A.; Picone, D. The α-to-β Conformational Transition of Alzheimer’s Aβ-(1-42) Peptide in Aqueous Media Is Reversible: A Step by Step Conformational Analysis Suggests the Location of β Conformation Seeding. ChemBioChem 2006, 7, 257–267.
67. Economou, N.J.; Giammona, M.J.; Do, T.D.; Zheng, X.; Teplow, D.B.; Buratto, S.K.; Bowers, M.T. Amyloid β-Protein Assembly and Alzheimer’s Disease: Dodecamers of Aβ42, but Not of Aβ40, Seed Fibril Formation. J. Am. Chem. Soc. 2016, 138, 1772–1775.
68. Shigemitsu, Y.; Iwaya, N.; Goda, N.; Matsuzaki, M.; Tenno, T.; Narita, A.; Hoshi, M.; Hiroaki, H. Nuclear Magnetic Resonance Evidence for the Dimer Formation of Beta Amyloid Peptide 1–42 in 1,1,1,3,3,3-Hexafluoro-2-Propanol. Anal. Biochem. 2016, 498, 59–67.
69. Mehrazma, B.; Rauk, A. Exploring Amyloid-β Dimer Structure Using Molecular Dynamics Simulations. J. Phys. Chem. A 2019, 123, 4658–4670.
70. Zhao, L.N.; Long, H.W.; Mu, Y.; Chew, L.Y. The Toxicity of Amyloid ß Oligomers. Int. J. Mol. Sci. 2012, 13, 7303–7327.
71. Sengupta, U.; Nilson, A.N.; Kayed, R. The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy. EBioMedicine 2016, 6, 42–49.
72. Rauk, A. Why Is the Amyloid Beta Peptide of Alzheimer’s Disease Neurotoxic? Dalton Trans. 2008, 1273–1282.
73. Kandel, N.; Zheng, T.; Huo, Q.; Tatulian, S.A. Membrane Binding and Pore Formation by a Cytotoxic Fragment of Amyloid β Peptide. J. Phys. Chem. B 2017, 121, 10293–10305.
74. Shirwany, N.A.; Payette, D.; Xie, J.; Guo, Q. The Amyloid Beta Ion Channel Hypothesis of Alzheimer’s Disease. Neuropsychiatr. Dis. Treat. 2007, 3, 597–612.
75. Arispe, N.; Pollard, H.B.; Rojas, E. Giant Multilevel Cation Channels Formed by Alzheimer Disease Amyloid Beta-Protein [A Beta P-(1-40)] in Bilayer Membranes. Proc. Natl. Acad. Sci. USA 1993, 90, 10573–10577.
76. Di Scala, C.; Yahi, N.; Boutemeur, S.; Flores, A.; Rodriguez, L.; Chahinian, H.; Fantini, J. Common Molecular Mechanism of Amyloid Pore Formation by Alzheimer’s β-Amyloid Peptide and α-Synuclein. Sci. Rep. 2016, 6, 28781.
77. Venko, K.; Novič, M.; Stoka, V.; Žerovnik, E. Prediction of Transmembrane Regions, Cholesterol, and Ganglioside Binding Sites in Amyloid-Forming Proteins Indicate Potential for Amyloid Pore Formation. Front. Mol. Neurosci. 2021, 14, 619496.
78. Wärmländer, S.K.T.S.; Österlund, N.; Wallin, C.; Wu, J.; Luo, J.; Tiiman, A.; Jarvet, J.; Gräslund, A. Metal-binding to the Amyloid-β Peptides in the Presence of Biomembranes: Potential Mechanisms of Cell Toxicity. J. Biol. Inorg. Chem. JBIC Publ. Soc. Biol. Inorg. Chem. 2019, 24, 1189–1196.
79. Sato, Y.; Takiguchi, M.; Tamano, H.; Takeda, A. Extracellular Zn2+-Dependent Amyloid-Β1-42 Neurotoxicity in Alzheimer’s Disease Pathogenesis. Biol. Trace Elem. Res. 2021, 199, 53–61.
80. Bode, D.C.; Baker, M.D.; Viles, J.H. Ion Channel Formation by Amyloid-Β42 Oligomers but Not Amyloid-Β40 in Cellular Membranes. J. Biol. Chem. 2017, 292, 1404–1413.
81. Serra-Batiste, M.; Ninot-Pedrosa, M.; Puig, E.; Ciudad, S.; Gairí, M.; Carulla, N. Preparation of a Well-Defined and Stable β-Barrel Pore-Forming Aβ42 Oligomer. In Amyloid Proteins; Sigurdsson, E.M., Calero, M., Gasset, M., Eds.; Springer: New York, NY, USA, 2018; Volume 1779, pp. 13–22. ISBN 978-1-4939-7815-1.
82. Di Scala, C.; Troadec, J.-D.; Lelièvre, C.; Garmy, N.; Fantini, J.; Chahinian, H. Mechanism of Cholesterol-Assisted Oligomeric Channel Formation by a Short Alzheimer β-Amyloid Peptide. J. Neurochem. 2014, 128, 186–195.
83. Bocharov, E.V.; Mineev, K.S.; Pavlov, K.V.; Akimov, S.A.; Kuznetsov, A.S.; Efremov, R.G.; Arseniev, A.S. Helix-Helix Interactions in Membrane Domains of Bitopic Proteins: Specificity and Role of Lipid Environment. Biochim. Biophys. Acta BBA Biomembr. 2017, 1859, 561–576.
84. Bocharov, E.V.; Sharonov, G.V.; Bocharova, O.V.; Pavlov, K.V. Conformational Transitions and Interactions Underlying the Function of Membrane Embedded Receptor Protein Kinases. Biochim. Biophys. Acta BBA Biomembr. 2017, 1859, 1417–1429.
85. Pavlov, K.V.; Akimov, S.A.; Batishchev, O.V.; Chekashkina, K.V.; Bashkirov, P.V.; Bocharov, E.V. Protein-Lipid Interplay in Vital Biological Functions. In Protein-Lipid Interactions: Perspectives, Techniques and Challenges; Catalá, A., Ed.; Nova Science Publishers: Harpark, NY, USA, 2018; pp. 133–199. ISBN 978-1-5361-3125-3.
86. Limbocker, R.; Chia, S.; Ruggeri, F.S.; Perni, M.; Cascella, R.; Heller, G.T.; Meisl, G.; Mannini, B.; Habchi, J.; Michaels, T.C.T.; et al. Trodusquemine Enhances Aβ 42 Aggregation but Suppresses Its Toxicity by Displacing Oligomers from Cell Membranes. Nat. Commun. 2019, 10, 225.
87. Smith, D.G.; Cappai, R.; Barnham, K.J. The Redox Chemistry of the Alzheimer’s Disease Amyloid Beta Peptide. Biochim. Biophys. Acta 2007, 1768, 1976–1990.
88. Džinić, T.; Dencher, N.A. Oxygen Concentration and Oxidative Stress Modulate the Influence of Alzheimer’s Disease Aβ1-42 Peptide on Human Cells. Oxid. Med. Cell. Longev. 2018, 2018, 7567959.
89. Shafrir, Y.; Durell, S.; Arispe, N.; Guy, H.R. Models of Membrane-Bound Alzheimer’s Abeta Peptide Assemblies. Proteins 2010, 78, 3473–3487.
90. Yu, Y.; Yin, T.; Peng, Q.; Kong, L.; Li, C.; Tang, D.; Yin, X. Simultaneous Monitoring of Amyloid-β (Aβ) Oligomers and Fibrils for Effectively Evaluating the Dynamic Process of Aβ Aggregation. ACS Sens. 2019, 4, 471–478.
91. Shea, D.; Hsu, C.-C.; Bi, T.M.; Paranjapye, N.; Childers, M.C.; Cochran, J.; Tomberlin, C.P.; Wang, L.; Paris, D.; Zonderman, J.; et al. α-Sheet Secondary Structure in Amyloid β-Peptide Drives Aggregation and Toxicity in Alzheimer’s Disease. Proc. Natl. Acad. Sci. USA 2019, 116, 8895–8900.
92. Ono, K.; Yamada, M. Low-n Oligomers as Therapeutic Targets of Alzheimer’s Disease. J. Neurochem. 2011, 117, 19–28.
93. Kreutzer, A.G.; Hamza, I.L.; Spencer, R.K.; Nowick, J.S. X-ray Crystallographic Structures of a Trimer, Dodecamer, and Annular Pore Formed by an Aβ17-36 β-Hairpin. J. Am. Chem. Soc. 2016, 138, 4634–4642.
94. Lendel, C.; Bjerring, M.; Dubnovitsky, A.; Kelly, R.T.; Filippov, A.; Antzutkin, O.N.; Nielsen, N.C.; Härd, T. A Hexameric Peptide Barrel as Building Block of Amyloid-β Protofibrils. Angew. Chem. Int. Ed. Engl. 2014, 53, 12756–12760.
95. Norlin, N.; Hellberg, M.; Filippov, A.; Sousa, A.A.; Gröbner, G.; Leapman, R.D.; Almqvist, N.; Antzutkin, O.N. Aggregation and Fibril Morphology of the Arctic Mutation of Alzheimer’s Aβ Peptide by CD, TEM, STEM and in Situ AFM. J. Struct. Biol. 2012, 180, 174–189.
96. Ciudad, S.; Puig, E.; Botzanowski, T.; Meigooni, M.; Arango, A.S.; Do, J.; Mayzel, M.; Bayoumi, M.; Chaignepain, S.; Maglia, G.; et al. Aβ(1-42) Tetramer and Octamer Structures Reveal Edge Conductivity Pores as a Mechanism for Membrane Damage. Nat. Commun. 2020, 11, 3014.
97. Nguyen, H.L.; Krupa, P.; Hai, N.M.; Linh, H.Q.; Li, M.S. Structure and Physicochemical Properties of the Aβ42 Tetramer: Multiscale Molecular Dynamics Simulations. J. Phys. Chem. B 2019, 123, 7253–7269.
98. Snyder, S.W.; Ladror, U.S.; Wade, W.S.; Wang, G.T.; Barrett, L.W.; Matayoshi, E.D.; Huffaker, H.J.; Krafft, G.A.; Holzman, T.F. Amyloid-beta aggregation: Selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys. J. 1994, 67, 1216–1228.
99. Jarrett, J.T.; Berger, E.P.; Lansbury, P.T., Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer’s disease. Biochemistry 1993, 32, 4693–4697.
100. Poma, A.B.; Chwastyk, M.; Cieplak, M. Elastic moduli of biological fibers in a coarse-grained model: Crystalline cellulose and β-amyloids. Phys. Chem. Chem. Phys. 2017, 19, 28195–28206.
101. Poma, A.B.; Guzman, H.V.; Li, M.S.; Theodorakis, P.E. Mechanical and thermodynamic properties of Aβ42, Aβ40, and α-synuclein fibrils: A coarse-grained method to complement experimental studies. Beilstein J. Nanotechnol. 2019, 10, 500–513.
102. Ruggeri, F.S.; Adamcik, J.; Jeong, J.S.; Lashuel, H.A.; Mezzenga, R.; Dietler, G. Influence of the β-sheet content on the mechanical properties of aggregates during amyloid fibrillization. Angew. Chem. Int. Ed. Engl. 2015, 54, 2462–2466.
103. Lührs, T.; Ritter, C.; Adrian, M.; Riek-Loher, D.; Bohrmann, B.; Döbeli, H.; Schubert, D.; Riek, R. 3D Structure of Alzheimer’s Amyloid-β (1–42) Fibrils. Proc. Natl. Acad. Sci. USA 2005, 102, 17342–17347.
104. Paravastu, A.K.; Leapman, R.D.; Yau, W.-M.; Tycko, R. Molecular Structural Basis for Polymorphism in Alzheimer’s β-Amyloid Fibrils. Proc. Natl. Acad. Sci. USA 2008, 105, 18349–18354.
105. Lu, J.-X.; Qiang, W.; Yau, W.-M.; Schwieters, C.D.; Meredith, S.C.; Tycko, R. Molecular Structure of β-Amyloid Fibrils in Alzheimer’s Disease Brain Tissue. Cell 2013, 154, 1257–1268.
106. Kodali, R.; Williams, A.D.; Chemuru, S.; Wetzel, R. Aβ(1–40) Forms Five Distinct Amyloid Structures Whose β-Sheet Contents and Fibril Stabilities Are Correlated. J. Mol. Biol. 2010, 401, 503–517.
107. Goodsell, D.S.; Dutta, S.; Zardecki, C.; Voigt, M.; Berman, H.M.; Burley, S.K. The RCSB PDB “Molecule of the Month”: Inspiring a Molecular View of Biology. PLoS Biol. 2015, 13, e1002140.
108. Gremer, L.; Schölzel, D.; Schenk, C.; Reinartz, E.; Labahn, J.; Ravelli, R.B.G.; Tusche, M.; Lopez-Iglesias, C.; Hoyer, W.; Heise, H.; et al. Fibril Structure of Amyloid-β(1–42) by Cryo–Electron Microscopy. Science 2017, 358, 116–119.
109. Schenk, D.; Basi, G.S.; Pangalos, M.N. Treatment Strategies Targeting Amyloid β-Protein. Cold Springer Harb. Perspect. Med. 2012, 2, a006387.
110. Chen, Y.; Fu, A.K.Y.; Ip, N.Y. Synaptic Dysfunction in Alzheimer’s Disease: Mechanisms and Therapeutic Strategies. Pharmacol. Ther. 2019, 195, 186–198.
111. Cummings, J.; Lee, G.; Ritter, A.; Sabbagh, M.; Zhong, K. Alzheimer’s Disease Drug Development Pipeline: 2020. Alzheimer’s Dement. Transl. Res. Clin. Interv. 2020, 6, e12050.
112. Fantini, J.; Chahinian, H.; Yahi, N. Progress toward Alzheimer’s Disease Treatment: Leveraging the Achilles’ Heel of Aβ Oligomers? Protein Sci. Publ. Protein Soc. 2020, 29, 1748–1759.
113. Heller, G.T.; Aprile, F.A.; Michaels, T.C.T.; Limbocker, R.; Perni, M.; Ruggeri, F.S.; Mannini, B.; Löhr, T.; Bonomi, M.; Camilloni, C.; et al. Small-Molecule Sequestration of Amyloid-β as a Drug Discovery Strategy for Alzheimer’s Disease. Sci. Adv. 2020, 6.
114. Di, L. Strategic Approaches to Optimizing Peptide ADME Properties. AAPS J. 2015, 17, 134–143.
115. Craik, D.J.; Fairlie, D.P.; Liras, S.; Price, D. The Future of Peptide-Based Drugs. Chem. Biol. Drug Des. 2013, 81, 136–147.
116. Funke, S.A.; Willbold, D. Peptides for Therapy and Diagnosis of Alzheimer’s Disease. Curr. Pharm. Des. 2012, 18, 755–767.
117. Li, X.; Zhang, X.; Ladiwala, A.R.A.; Du, D.; Yadav, J.K.; Tessier, P.M.; Wright, P.E.; Kelly, J.W.; Buxbaum, J.N. Mechanisms of Transthyretin Inhibition of β-Amyloid Aggregation in Vitro. J. Neurosci. Off. J. Soc. Neurosci. 2013, 33, 19423–19433.
118. Stein, T.D.; Johnson, J.A. Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein Is Associated with Increased Levels of Transthyretin and the Activation of Cell Survival Pathways. J. Neurosci. Off. J. Soc. Neurosci. 2002, 22, 7380–7388.
119. Volpina, O.M.; Samokhin, A.N.; Koroev, D.O.; Nesterova, I.V.; Volkova, T.D.; Medvinskaya, N.I.; Nekrasov, P.V.; Tatarnikova, O.G.; Kamynina, A.V.; Balasanyants, S.M.; et al. Synthetic Fragment of Receptor for Advanced Glycation End Products Prevents Memory Loss and Protects Brain Neurons in Olfactory Bulbectomized Mice. J. Alzheimers Dis. JAD 2018, 61, 1061–1076.
120. Kamynina, A.; Esteras, N.; Koroev, D.O.; Angelova, P.R.; Volpina, O.M.; Abramov, A.Y. Activation of RAGE Leads to the Release of Glutamate from Astrocytes and Stimulates Calcium Signal in Neurons. J. Cell. Physiol. 2021.
121. Barykin, E.P.; Garifulina, A.I.; Tolstova, A.P.; Anashkina, A.A.; Adzhubei, A.A.; Mezentsev, Y.V.; Shelukhina, I.V.; Kozin, S.A.; Tsetlin, V.I.; Makarov, A.A. Tetrapeptide Ac-HAEE-NH2 Protects A4β2 NAChR from Inhibition by Aβ. Int. J. Mol. Sci. 2020, 21, 6272.
122. Funke, S.A.; Willbold, D. Mirror Image Phage Display—A Method to Generate D-Peptide Ligands for Use in Diagnostic or Therapeutical Applications. Mol. Biosyst. 2009, 5, 783–786.
123. Wiesehan, K.; Buder, K.; Linke, R.P.; Patt, S.; Stoldt, M.; Unger, E.; Schmitt, B.; Bucci, E.; Willbold, D. Selection of D-Amino-Acid Peptides That Bind to Alzheimer’s Disease Amyloid Peptide Abeta1-42 by Mirror Image Phage Display. Chembiochem. Eur. J. Chem. Biol. 2003, 4, 748–753.
124. Ziehm, T.; Brener, O.; van Groen, T.; Kadish, I.; Frenzel, D.; Tusche, M.; Kutzsche, J.; Reiß, K.; Gremer, L.; Nagel-Steger, L.; et al. Increase of Positive Net Charge and Conformational Rigidity Enhances the Efficacy of D-Enantiomeric Peptides Designed to Eliminate Cytotoxic Aβ Species. ACS Chem. Neurosci. 2016, 7, 1088–1096.
125. Willbold, D.; Kutzsche, J. Do We Need Anti-Prion Compounds to Treat Alzheimer’s Disease? Molecules 2019, 24, 2237.
126. Uversky, V.N. The multifaceted roles of intrinsic disorder in protein complexes. FEBS Lett. 2015, 589, 2498–2506.